Natural Product (NP) Details
General Information of the NP (ID: NP4902) | |||||
---|---|---|---|---|---|
Name |
Streptozocin
|
||||
Synonyms |
streptozocin; STREPTOZOTOCIN; streptozosin; Zanosar; 18883-66-4; Estreptozocina; Streptozocine; Streptozocinium; Streptozocinum; alpha-Streptozocin; streptozotocin (stz); N-D-Glucosyl-(2)-N'-nitrosomethylurea; C8H15N3O7; CHEBI:9288; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; 66395-18-4; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Desoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; UNII-8H27GUR065; 8H27GUR065; MFCD00006607; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; alkylating agent; DSSTox_CID_1282; STZ; DSSTox_RID_76055; DSSTox_GSID_21282; binds to DNA; Zanosar (TN); SR-05000001720; 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]-D-glucose; 2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-alpha-D-glucopyranose; NCGC00016738-01; CAS-18883-66-4; Spectrum_000960; Streptozotocin - Zanosar; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose; Prestwick3_000732; Spectrum2_000062; Spectrum3_001087; Spectrum4_001244; Spectrum5_001047; Epitope ID:134282; N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; SCHEMBL4748; Streptozocin; Streptozotocin; 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; CHEMBL1603; BSPBio_000684; BSPBio_002734; KBioGR_001768; KBioSS_001440; MLS004774123; DivK1c_000531; SPECTRUM1500543; SPBio_000243; BPBio1_000754; Streptozocin (JAN/USAN/INN); DTXSID2021282; BCBcMAP01_000142; HMS501K13; KBio1_000531; KBio2_001440; KBio2_004008; KBio2_006576; KBio3_001954; NINDS_000531; HMS1921A07; HMS2092I09; HMS2097C06; HMS3714C06; Pharmakon1600-01500543; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; ACT03364; ZINC3977737; Streptozocin, >=98.0% (HPLC); Tox21_110585; Tox21_201859; Tox21_302974; CCG-39870; NSC757321; s1312; AKOS025310730; Tox21_110585_1; DB00428; NSC-757321; IDI1_000531; SMP1_000282; NCGC00178500-01; NCGC00178500-02; NCGC00178500-03; NCGC00178500-04; NCGC00178500-07; NCGC00256594-01; NCGC00259408-01; 1-Methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-3-yl)urea; 1-methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)urea; SMR001233317; SBI-0051517.P003; AB00513906; SW199198-2; C07313; D05932; 24975-EP2275420A1; 24975-EP2277858A1; 24975-EP2292227A2; 24975-EP2295053A1; 24975-EP2298767A1; 24975-EP2314574A1; 27771-EP2272827A1; 27771-EP2295055A2; 27771-EP2295416A2; 27771-EP2295426A1; 27771-EP2295427A1; 27771-EP2298748A2; 27771-EP2298764A1; 27771-EP2298765A1; 27771-EP2298778A1; 27771-EP2305642A2; 27771-EP2308833A2; 27771-EP2308861A1; 27771-EP2311453A1; 27771-EP2311842A2; 27771-EP2314587A1; 27773-EP2277858A1; 27773-EP2292227A2; 27773-EP2298767A1; 27773-EP2314587A1; AB00052092-03; AB00052092_04; AB00052092_05; 883S664; Q257331; SR-01000939745; SR-01000939745-3; SR-05000001720-1; SR-05000001720-2; W-201687; Streptozocin, Vetec(TM) reagent grade, 98%, powder; Streptozocin, >=75% alpha-anomer basis, >=98% (HPLC), powder; alpha-D-Glucopyranose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-; 3-methyl-3-nitroso-1-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]urea
Click to Show/Hide
|
||||
Species Origin | Streptomyces achromogenes ... | Click to Show/Hide | |||
Streptomyces achromogenes | |||||
Disease | Pancreatic cancer [ICD-11: 2C10] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C8H15N3O7
|
||||
PubChem CID | |||||
Canonical SMILES |
CN(C(=O)NC1C(C(C(OC1O)CO)O)O)N=O
|
||||
InChI |
1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1
|
||||
InChIKey |
ZSJLQEPLLKMAKR-GKHCUFPYSA-N
|
||||
CAS Number |
CAS 18883-66-4
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Medical records | |||||
Experimental
Result(s) |
The combination of STZ and 5-FU is effective in the treatment of pNETs in terms of survival and radiological response and has an acceptable toxicity profile. | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
5-fluorouracil + Doxorubicin | Click to Show/Hide the Molecular Data of This Drug | |||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Clinical trial | |||||
Experimental
Result(s) |
The use of FAS before liver resection is associated with improved OS compared with surgery alone among patients with advanced synchronous pancreatic neuroendocrine liver metastases. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Human Deoxyribonucleic acid (hDNA) | Molecule Info | [4] |
